Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gp100:209-217(210M) peptide vaccine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Vaccine Therapy in Treating Patients With Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000068299, NCI-00-C-0216, NCI-2391, 2391, NCT00020358
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000068514, NCI-01-C-0074, NCI-2910, 2910, NCT00020475
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000069251, NCI-02-C-0106H, NCI-5743, 5743, NCT00032045
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000335441, NCI-03-C-0299, NCI-6210, 6210, NCT00072085
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: 10M-03-1, LAC-USC-10M-03-1, NCI-6262, LAC-USC-033307, CDR0000480137, NCI-2009-00050, 6262, NCT00334776
Phase II Randomized Study of Ipilimumab With Versus Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Previously Treated, HLA-A*0201 Positive Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0159, NCI-P6951, MDX-NCI-06-C-0159, NCT00357461
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 04-173, NCI-2009-00159, PCI-IRB-0607048, CDR0000544402, PCI-04173, 7357, NCT00471471
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: MCC-15400, NCI-P-7997, CA209-006/007, 10-15526-99-01, 7997, NCT01176461
Start Over